Intelligence for the Dealmaking Community since 1965
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
This is premium content

To read the full story, please upgrade your plan.

Upgrade plan
Login to your account

Pharmaceuticals

image
Healthcare
Mergers & Acquisitions 2025 Deals of the Year: Recursion Acquired Exscientia
The acquisition represents a measured risk taken towards innovation and betting on a new way to discover drugs.
May 5, 2025
KKR
Healthcare
KKR Reportedly Considers Selling $750M Stake in JB Pharma
KKR may seek to reduce its stake in JB Chemicals to about 25 percent from the almost 54 percent it currently holds.
November 6, 2024
image
Healthcare
The Drama Behind CD&R’s Buyout of Sanofi OTC Business
Sanofi’s decision triggered criticism across France’s political landscape and even prompted President Emmanuel Macron’s pro-business party to voice concern.
October 24, 2024
Stada was founded in the late 19th century
Private Equity
GTCR Reportedly in Advanced Talks to Acquire German Drugmaker Stada
PE firms have been pouring money into generic drugs as pharmaceutical companies focus more on developing treatments for rare diseases.
September 11, 2024

Trending

1.
Mid-Market M&A Takes a Summer Break
August 6, 2026
2.
PE Fundraising Is Becoming a Package Deal
August 13, 2026
3.
Secondaries Edge: Liquidity, Conflicts and the Fine Print
August 5, 2026
4.
Aviation Services M&A Takes Off
August 17, 2026
5.
GTCR Closes $1.25B Inaugural Capital Solutions Fund
July 29, 2026
6.
Why the Biggest Middle-Market Funds Keep Getting Bigger
August 10, 2026
7.
RIA Megadeals Squeeze the Middle Market
August 4, 2026
8.
The Fast Lane to Winning a Lower Middle-Market Deal
July 29, 2026
9.
Secondaries Edge: The Never-Ending Hold
August 19, 2026